Deals & Cases

CHF 12.5 Million financing round in Alentis Therapeutics AG

2 May 2019 – Walder Wyss advises BiomedPartners AG and BB Pureos Bioventures as Co-Lead Investors in connection with Alentis Therapeutics AG’s Series A Financing Round in the amount of CHF 12.5 mio. Alentis develops novel therapeutics in advanced liver disease and cancer. The Financing Round was further subscribed by BPI France, Schroder Adveq and the German High-Tech Gründerfonds..

The Walder Wyss team comprises Alexander Gutmans (Partner, Corporate/Venture Capital), Robert von Rosen (Partner, Corporate/M&A), Vanessa C. Haubensak (Associate, Corporate/M&A) and Manuel Bigler (Associate, IP/IT).